Organon & Co. (NYSE:OGN) Price Target Raised to $20.00

Organon & Co. (NYSE:OGN - Get Free Report) had its price target increased by stock analysts at The Goldman Sachs Group from $18.00 to $20.00 in a report released on Friday, Benzinga reports. The firm presently has a "neutral" rating on the stock. The Goldman Sachs Group's price objective would suggest a potential upside of 1.99% from the stock's current price.

Separately, Piper Sandler lifted their target price on Organon & Co. from $22.00 to $24.00 and gave the stock an "overweight" rating in a report on Monday.

Organon & Co. Trading Up 0.6 %

Shares of NYSE:OGN traded up $0.11 during trading on Friday, hitting $19.61. 3,217,321 shares of the company were exchanged, compared to its average volume of 2,725,945. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $24.08. The stock has a market cap of $5.04 billion, a price-to-earnings ratio of 4.88, a P/E/G ratio of 0.89 and a beta of 0.81. The firm has a fifty day moving average price of $18.17 and a two-hundred day moving average price of $15.75.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its earnings results on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, topping analysts' consensus estimates of $0.73 by $0.14. The business had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a net margin of 16.33% and a negative return on equity of 212.00%. As a group, research analysts predict that Organon & Co. will post 4.1 EPS for the current year.

Insider Buying and Selling

In other news, insider Kirke Weaver bought 2,720 shares of the stock in a transaction that occurred on Thursday, February 22nd. The stock was acquired at an average price of $18.36 per share, with a total value of $49,939.20. Following the completion of the purchase, the insider now directly owns 15,181 shares of the company's stock, valued at $278,723.16. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.17% of the stock is currently owned by insiders.

Institutional Trading of Organon & Co.

Several large investors have recently modified their holdings of OGN. Harvest Fund Management Co. Ltd lifted its holdings in shares of Organon & Co. by 495.5% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 1,602 shares of the company's stock worth $28,000 after purchasing an additional 1,333 shares in the last quarter. Lindbrook Capital LLC lifted its stake in Organon & Co. by 348.3% during the 4th quarter. Lindbrook Capital LLC now owns 1,838 shares of the company's stock valued at $27,000 after acquiring an additional 1,428 shares in the last quarter. Headlands Technologies LLC bought a new position in Organon & Co. during the 3rd quarter valued at $35,000. Gladius Capital Management LP lifted its stake in Organon & Co. by 65.1% during the 4th quarter. Gladius Capital Management LP now owns 2,176 shares of the company's stock valued at $31,000 after acquiring an additional 858 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in Organon & Co. by 97.7% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,246 shares of the company's stock valued at $39,000 after acquiring an additional 1,110 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company's stock.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.